Press Releases from Crucell N.V. (7 total)
direct/ Crucell N.V. (NL) - CRUCELL AND BERNA BIOTECH: TOGETHER CREATING THE LE …
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA
This announcement and related…
Crucell N.V. (NL) - Crucell and DSM Announce PER.C6® Licensing Agreement with …
Crucell and DSM Announce PER.C6® Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax
Leiden/Sittard, The Netherlands, October 19, 2005 - Dutch…
Crucell N.V. (NL) - Crucell Announces Third Quarter 2005 Results
Crucell Announces Third Quarter 2005 Results
- Strong increase in quarter and year-to-date revenues.
- New development programs in rabies and tuberculosis.
- Further AdVac®-based vaccine…
Crucell N.V. (NL) - Crucell Updates Progress in Scale-up of Cell-culture-based I …
Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs
Leiden, The Netherlands, October 13, 2005 - Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it…
Crucell N.V. (NL) - Merck and Co., Inc. Exercises Option on PER.C6® License for …
Merck and Co., Inc. Exercises Option on PER.C6® License for Adenovirus-based Vaccine Against Hepatitis C
Leiden, The Netherlands, October 10, 2005 - Dutch biotechnology company Crucell…
Crucell N.V. (NL) - Crucell Secures EUR 2 Million Grant from Dutch Ministry of …
Crucell Secures EUR 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-resistant Bacterial Infections
Leiden, The Netherlands, September 16, 2005 -…
Crucell N.V. (NL) - Crucell and Aeras Announce Progress in TB Vaccine Program
Crucell and Aeras Announce Progress in TB Vaccine Program
Leiden, The Netherlands, September 8, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and…
Go To Page:
